Therapeutics Acquisition Corp. License Agreements
2 Contracts & Agreements
- First Amendment dated November 8, 2022 to the Exclusive License and Commercialization Agreement dated December 16, 2020 between POINT; the Canadian Molecular Probe Consortium; the... (Filed With SEC on March 27, 2023)
- Exclusive License and Commercialization Agreement, dated December 16, 2020, by and between POINT Biopharma Inc., Canadian Molecular Probe Consortium, the Centre for Probe... (Filed With SEC on March 23, 2021)
